Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

DRUG4 trials

Sponsors

Northern California Melanoma Center, Muscular Dystrophy Association, United Therapeutics, Hoffmann-La Roche

Conditions

Malignant MelanomaMyasthenia GravisNeuroblastomaTriple-Negative Breast Cancer

Early Phase 1

A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis

Muscular Dystrophy AssociationMyasthenia Gravis

Start: 2012-04-30End: 2013-12-31Target: 12Updated: 2012-03-15

Phase 1

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

CompletedNCT01592045

United TherapeuticsNeuroblastoma

Start: 2012-08-31End: 2014-06-30Updated: 2015-09-23

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

CompletedNCT04584112

Hoffmann-La RocheTriple-Negative Breast Cancer

Start: 2020-09-28End: 2023-03-08Updated: 2023-03-15

Phase 2

GM-CSF as Adjuvant Therapy of Melanoma

CompletedNCT00350597

Northern California Melanoma CenterMalignant Melanoma

Start: 2004-09-30End: 2010-07-31Target: 50Updated: 2006-07-11

Related Papers

Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.

2025-11-25